BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
2.120
-0.190 (-8.23%)
At close: Mar 28, 2025, 4:00 PM
2.090
-0.030 (-1.42%)
After-hours: Mar 28, 2025, 7:57 PM EDT
BioXcel Therapeutics Employees
BioXcel Therapeutics had 74 employees as of December 31, 2023. The number of employees decreased by 109 or -59.56% compared to the previous year.
Employees
74
Change (1Y)
-109
Growth (1Y)
-59.56%
Revenue / Employee
$30,622
Profits / Employee
-$805,392
Market Cap
6.58M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
BTAI News
- 3 days ago - BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024 - GlobeNewsWire
- 19 days ago - BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewsWire
- 23 days ago - BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewsWire
- 26 days ago - BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering - GlobeNewsWire
- 27 days ago - BioXcel Therapeutics Announces $14 Million Registered Direct Offering - GlobeNewsWire
- 27 days ago - BioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer's Dementia - GlobeNewsWire
- 4 weeks ago - BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule - GlobeNewsWire
- 7 weeks ago - BioXcel Therapeutics Announces Reverse Stock Split - GlobeNewsWire